Short and long-term effects of hydralazine and combined hydralazine and prenalterol therapy in patients with congestive heart failure.
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D006328:Cardiac Catheterization; D002302:Cardiac Output / Q000187:drug effects; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D005082:Physical Exertion; D011217:Practolol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011294:Prenalterol; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D006830:Hydralazine; D011294:Prenalterol; D011217:Practolol